| GTO ID | GTC3229 |
| Trial ID |
NCT05610280
|
| Disease |
Arteriosclerotic Cardiovascular Disease
|
Hypertriglyceridemia
|
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Olezarsen|ISIS 678354|IONIS-APOCIII-LRx|AKCEA-APOCIII-LRx |
| Co-treatment | Clopidogrel |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia |
| Year | 2022 |
| Country | Bulgaria|Canada|Czechia|Denmark|France|Hungary|Italy|Netherlands|Norway|Poland|Portugal|Slovakia|Spain|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 678354-CS9|2022-501486-53 |